Despite the successes in immuno-oncology, less than 50% of individuals with cancer obtain a durable response. That’s why GlycoTherapeutics is on a mission to improve cancer treatment. Their first-in-class anticancer drugs target sugars that play a critical role in tumor progression, offering new hope for cancer patients everywhere.
Leendert van den Bos
Complies with the following Sustainable Development Goals:
SDG 3: Good health and wellbeing